Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Stock Watch

Set Alert for Stock Watch

Stock Watch: Pfizer’s Second-Quarter Pandemic And Base Businesses Diverge

Pfizer recorded the largest quarterly sales in its history as its COVID-19 franchise easily outweighed the currency issues that are challenging other companies. But expectations for a quick end to the pandemic have wiped these gains from Pfizer’s stock price.

Stock Watch Companies

Stock Watch: Robust Diagnostics And Biosimilar Erosion Vie In Roche’s Q2

Roche’s stock price has underperformed in the last nine months in spite of a natural hedge on the strong US dollar that has troubled most other profitable pharma companies. Has Roche become a value stock?

Stock Watch Sales & Earnings

Stock Watch: Contrasting Novartis And J&J Stock Movements Defy Explanation

Among equity investors there is concern about the impact of macroeconomic headwinds on second-quarter earnings. The first two big life sciences companies’ reports did nothing to alleviate those concerns.

Stock Watch Sales & Earnings

Stock Watch: Getting Real About Antibody-Drug Conjugates’ Potential

Antibody-drug conjugates have come a long way in two decades but pricing, defined target expression levels, toxicity and possibly the competition may defuse recent fireworks.

Stock Watch Clinical Trials

Stock Watch: Debt And Biotech Do Not Mix

Even with higher interest rates, some debt on the balance sheets of profitable biotechs is healthy. However, among loss-making biotechs and in the current environment, raising new debt has unhealthy connotations.

Stock Watch Financing

Stock Watch: The Stubborn Hurdle Of Chronic Hepatitis B

Most of the money raised by biotech companies to address chronic hepatitis B has resulted in failed programs. But wait, a glimmer of light from yonder pharma breaks.

Stock Watch Vaccines

Stock Watch: Protocol Changes Preface Poor Trial Outcomes

It takes a lot of negotiation with regulators, advisory boards, and alignment between commercial and portfolio management teams to define and agree a clinical trial protocol. Why on earth would companies change it once a study is underway?

Stock Watch Clinical Trials

Stock Watch: Rare Diseases Beget Rare Profitability

Do rare disease drugs with tiny patient populations lie outside the profitability continuum that runs from small-molecule primary care products to specialist biologics?

Stock Watch Rare Diseases

Stock Watch: Cancer Combination Therapies Face Rising Bar

Improving efficacy by combining drugs has been a mainstay of cancer therapy but adding new targeted drugs together based on very early-stage data is not working out, especially when one of the drugs is barely active on its own.

Stock Watch Companies

Stock Watch: Academia’s Undiscovered Drug Developments

It is easy for university researchers to criticize the pharmaceutical sector’s R&D productivity when they ignore the contributions of all the drugs that have been approved, and all those that have been rejected.

Stock Watch Research & Development

Stock Watch: Biotech’s Commercial Laggards Drag On Sector

Some commercial-stage biotechnology companies blame the pandemic for their declining sales and continued losses. While an acquisition by a bigger company might once have been an aspiration, further fundraisings seem to be the more likely outcome.

Stock Watch Commercial

Stock Watch: One Acquisition Does Not Make A Biotech M&A Boom

Another blow-out quarter from Pfizer provided the impetus for an acquisition. But the history of recent commercial-stage biotech transactions and the risky nature of all early-stage companies suggest that the floodgates will not burst open.

Stock Watch M & A
UsernamePublicRestriction

Register